Skip to main content

Our Vision and Strategy

Our vision and strategy is to utilize our ApoptiCIDe-CE™  purposeful cell elimination gene therapy platform technology, validated in human patients, to remove unwanted cells in the body in appropriate clinical indications.

We believe targeting senescent cells for elimination using our clinical candidate vector ApoptiCIDe-CE-GERO-001 has the strongest Proof of Concept and the most favorable risk to benefit ratio for arresting or reversing aging of any other approach in the field of Geroscience and Longevity medicine.

Furthermore, we believe targeting adipocytes for elimination using our clinical candidate vector ApoptiCIDe-CE-WAT-001 for example, may provide a new rapid weight loss option, eliminating fat without affecting lean body or bone mass, for patients with morbid- or sarcopenic-obesity.

Our approach gives us a unique opportunity to intervene in the aging process in ways that were once thought impossible.

Our Leadership

Kevin Slawin, MD

Chairman and CEO

Kevin Slawin, M.D. is the Founder and CEO of Eos SENOLYTIX, Inc., a gerotherapeutics company whose lead programs are focused on proprietary senolytic peptides, that may restore the youthful balance of aged or “senescent” and young cells throughout the organs of the body. He was the founder of Bellicum Pharmaceuticals, Inc., leading Bellicum to a successful $161 million IPO in December, 2014.

Kevin Slawin, M.D. is the Founder and CEO of Eos SENOLYTIX, Inc., a gerotherapeutics company whose lead programs are focused on proprietary senolytic peptides, that may restore the youthful balance of aged or “senescent” and young cells throughout the organs of the body. He is also the Founder and CEO of Phoenix SENOLYTIX, Inc., a longevity company developing novel gene therapies targeting senescent cells, among other fundamental mechanisms of aging. He was the co-founder of Bellicum Pharmaceuticals, Inc., leading Bellicum to a successful $161 million IPO in December, 2014. He is also Founder, Chairman and CEO of PrintBio, Inc., the only clinical- and commercial-stage regenerative medicine company solving medical challenges with custom-engineered 3D-bioprinted living implants. He currently lives in Miami, FL where he is Founder and CEO of Miami Medicos, a membership organization of physicians, founders, executives, and investors catalyzing the healthcare entrepreneurial ecosystem in Miami and worldwide.

David Spencer, Ph.D

Chief Technology Officer

David is an internationally recognized leader in synthetic molecular biology with over 25 years of experience, focusing on biomedical applications with emphasis on regulation of vaccines and T cell immunotherapies. He is the scientific co-founder of Bellicum and its former Chief Scientific Officer.

David is an internationally recognized leader in synthetic molecular biology with over 25 years of experience, focusing on biomedical applications with emphasis on regulation of vaccines and T cell immunotherapies. He is the scientific co-founder of Bellicum and its former Chief Scientific Officer. Among his scientific inventions, he conceived of chemically induced dimerization (CID) in the early 90s and is the inventor or co-inventor of most of its initial clinical applications, such as the CaspaCIDe® safety switch and the inducible activation switch, iMC, which was built into the DeCIDe® vaccine platform and the GoCAR-T cell platform, including adapting both technologies for Bellicum’s dual-switch technologies, which have all now been purchased by MD Anderson Cancer Center. CID technology is now in use in 1000s of laboratories worldwide and forms the basis of many switch technologies being utilized in cellular therapies in preclinical work and clinically.

Before joining Bellicum, he served as the Vice Chairman of Pathology and Immunology at Baylor College of Medicine, where he was the Roger D Rossen Endowed Professor of Immunology. His lab focused on anti-cancer vaccination and animal modeling for prostate cancer, but his collaborative interests stretched into most areas of biology, such as Gene Regulation, Development, Cancer, Immunology and Aging. The animal models developed in his lab included the EZC-Prostate™ model for identifying and developing novel androgen axis inhibitors and the JOCK1 inducible prostate cancer model that demonstrated a critical inductive role of the Fibroblast Growth Factor Receptor 1(FGFR1) Axis in prostate cancer development.

He has published extensively in top scientific and medical journals, including Science, Nature, Nature Medicine, Molecular Cell, and NEJM and is also an inventor on at least 15 patent families, reflecting many areas of regulated cellular therapy. Dr. Spencer earned his BS in Chemistry (magna cum laude) at the University of California in San Diego and his Ph.D. in Biology from the Massachusetts Institute of Technology. He completed his postdoctoral degree at the Howard Hughes Medical Institute at Stanford University.

Kevin Slawin, MD

Chairman and CEO

Kevin Slawin, M.D. is the Founder and CEO of Eos SENOLYTIX, Inc., a longevity company whose lead program is focused on proprietary senolytic peptides, that may restore the youthful balance of aged or “senescent” and young cells throughout the organs of the body. He was the founder of Bellicum Pharmaceuticals, Inc., leading Bellicum to a successful $161 million IPO in December, 2014.

Kevin Slawin, M.D. is the Founder and CEO of Eos SENOLYTIX, Inc., a longevity company whose lead program is focused on proprietary senolytic peptides, that may restore the youthful balance of aged or “senescent” and young cells throughout the organs of the body. He is also the Founder and CEO of Phoenix SENOLYTIX, Inc., a longevity company developing novel gene therapies targeting senescent cells, among other fundamental mechanisms of aging. He was the co-founder of Bellicum Pharmaceuticals, Inc., leading Bellicum to a successful $161 million IPO in December, 2014. He is also Founder, Chairman and CEO of PrintBio, Inc., the only clinical- and commercial-stage regenerative medicine company solving medical challenges with custom-engineered 3D-bioprinted living implants. He currently lives in Miami, FL where he is Founder and CEO of Miami Medicos, a membership organization of physicians, founders, executives, and investors catalyzing the healthcare entrepreneurial ecosystem in Miami and worldwide.